Company Description
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada.
The company’s commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer’s disease.
Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer’s disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy.
Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
| Country | United States |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 71 |
| CEO | Michael McFadden |
Contact Details
Address: 1452 Hughes Street, Suite 200 Grapevine, Texas 76051 United States | |
| Phone | 858 344 4375 |
| Website | alphacognition.com |
Stock Details
| Ticker Symbol | ACOG |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001655923 |
| CUSIP Number | 00485A204 |
| ISIN Number | CA02074J5017 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Michael E. McFadden B.B.A. | Chief Executive Officer and Director |
| Kenneth Anthony Cawkell B.A., LL.B. | Founder, Consultant, Corporate Secretary and Director |
| Henry H. Du CPA | Vice President of Finance and Accounting and Interim Chief Financial Officer |
| Lauren D'Angelo M.B.A. | Chief Operating Officer |
| Dr. Denis G. Kay M.Sc., Ph.D. | Chief Scientific Officer |
| Timothy Ayers | Head of Compliance |
| Christine Reveal | Vice President of Marketing and Commercial Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 23, 2026 | 8-K | Current Report |
| May 22, 2026 | SCHEDULE 13G/A | Filing |
| May 14, 2026 | 10-Q | Quarterly Report |
| May 12, 2026 | SCHEDULE 13G/A | Filing |
| May 11, 2026 | SCHEDULE 13G/A | Filing |
| May 1, 2026 | 8-K/A | [Amend] Current report |
| Apr 30, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 20, 2026 | 8-K | Current Report |
| Apr 14, 2026 | 8-K | Current Report |